We are investigating Correvio Pharma Corp. (CORV) (“Correvio” or the “Company”) for potential violations of the federal securities laws.
On December 6, 2019, U.S. Food and Drug Administration (“FDA”) staffers reviewing Brinavess, Correvio’s atrial fibrillation treatment, announced that they did not believe that the drug’s benefits outweighed its risks. Specifically, the FDA noted that Brinavess was associated with “serious liabilities” including low blood pressure, irregular heartbeats in the lower heart chambers, and death. On this news, Correvio’s stock price fell $0.86 per share, or 39.81%, to close at $1.30 per share on December 6, 2019.